Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZUM vs Tamsulosin in BPH
NCT07169773Completed
- Start
- May 2022
- Primary completion
- May 2023
- Countries
- 1
01
Overview
Randomised, open-label trial (2 arms). Primary endpoints: International Prostate Symptom Score at 12 months, Maximum Urinary Flow Rate at 12 months and 2 more. Started May 2022; status: completed.
Beyond the preview
Go deeper on NCT07169773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169773.